Small Cell Lung Cancer Extensive Stage Clinical Trial
Official title:
A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
Status | Recruiting |
Enrollment | 41 |
Est. completion date | March 2028 |
Est. primary completion date | January 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Be at least 18 years of age and willing and able to provide a written informed consent - Have histologically/cytologically confirmed unresectable small cell lung carcinoma (SCLC), large cell neuroendocrine lung carcinoma (LCNEC), combined SCLC, or combined LCNEC as per WHO 2021 criteria - Subjects who have at least one prior line of standard treatment, and have progressed after or have had an insufficient response, and for whom standard treatment is intolerable, unlikely to confer significant clinical benefit, is no longer effective, or the subject declines further standard treatment - Have available formalin-fixed, paraffin-embedded tumor specimen in a tissue block or unstained serial slides accompanied by an associated pathology report prior to enrollment. Archival or fresh biopsy tissue is required - Presence of = 1 radiologically measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Life expectancy of at least 4 months - Have adequate organ function - Women of childbearing potential must have a negative pregnancy test at screening using a highly sensitive serum pregnancy test (ß-human chorionic gonadotropin [ß-hCG]) - All subjects must agree to practice a highly effective method of contraception (failure rate of <1% per year when used consistently and correctly) from the time of signing the informed consent form (ICF) to 1 year after receiving a LB2102 infusion - Women and men must agree not to donate eggs (ova, oocytes) or sperm, respectively, until at least 1 year after receiving a LB2102 infusion - Must have adequate leukapheresis material of non-mobilized cells available for manufacturing Exclusion Criteria: - Prior treatment with cellular immunotherapy (e.g., CAR-T) or gene therapy product - Prior treatment with DLL3-targeted therapy - Prior history of checkpoint inhibitor associated pneumonitis - Clinically significant ascites, pleural or peritoneal effusions - Primary acquired or inherited immunodeficiency syndromes - Known leptomeningeal metastases - Active or symptomatic brain metastasis. Subjects with treated brain metastasis are eligible provided additional requirements are met per protocol. - Active autoimmune disease receiving immunomodulatory treatments (e.g., cyclosporine or high dose systemic steroids) - Impaired cardiac function or clinically significant cardiac disease not controlled by medications - Previous or concurrent malignancy, excluding certain exceptions - Serious and /or uncontrolled medical condition that, in the Investigator's judgment, would cause unacceptable safety risk, interfere with study procedures or results, or compromise compliance with the protocol - Subjects with known active infection with HIV, hepatitis B, and/or hepatitis C virus (HBV/HCV) are not eligible unless additional protocol requirements are met. - Contraindications or life-threatening allergies, hypersensitivity, or intolerance to LB2102 excipients, such as dimethyl sulfoxide; or to fludarabine, cyclophosphamide, or tocilizumab - Ongoing toxicity of organ functions from previous anticancer therapy that has not resolved to Grade 1 or less, except for alopecia - Major surgery within 4 weeks prior to apheresis, or planned within 4 weeks after LB2102 administration - Pregnant or breast-feeding - Plans to become pregnant or breastfeed, or father a child within 1 year after receiving a LB2102 infusion - Previous history of allogeneic hematopoietic stem cell transplantation (HSCT), organ transplant, or in preparation for organ transplant |
Country | Name | City | State |
---|---|---|---|
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | University of Kentucky - Markey Cancer Center | Lexington | Kentucky |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Moffitt Cancer Center | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Legend Biotech USA Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To characterize the safety and tolerability of LB2102 and determine recommended dose for expansion (RDE) | Multiple doses will be tested to establish a recommended dose | 28 days | |
Primary | To further characterize the safety and tolerability of LB2102 with the RDE identified in the dose-escalation and determine the recommended Phase 2 dose (RP2D) | Treatment of additional patients at the recommended dose as identified in the initial dose escalation part of the study | 90 days | |
Secondary | To evaluate the preliminary efficacy of LB2102 | Measured by Response Evaluation Criteria In Solid Tumors (RECIST) | Through study completion, a minimum of 2 years | |
Secondary | To characterize the pharmacokinetics of LB2102 in blood | CAR-positive T cell counts in cells/microliter (µL) blood | Through study completion, a minimum of 2 years | |
Secondary | To evaluate the immunogenicity of LB2102 | Number of subjects with presence of anti-LB2102 antibodies | Through study completion, a minimum of 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02179528 -
Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)
|
Phase 2 | |
Recruiting |
NCT06030258 -
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05384015 -
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05745350 -
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
|
Phase 2 | |
Completed |
NCT03325816 -
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05856695 -
A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
Recruiting |
NCT05703971 -
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06429696 -
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00003496 -
Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT03059667 -
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03923270 -
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06348797 -
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
|
Phase 1 | |
Active, not recruiting |
NCT04462276 -
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
|
Phase 2 | |
Not yet recruiting |
NCT04967625 -
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
|
Phase 2 | |
Recruiting |
NCT04659785 -
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer(FA-ES-SCLC)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
Not yet recruiting |
NCT05066945 -
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
|
||
Recruiting |
NCT05945745 -
Molecular Analysis and Treatment Options of SCLC
|
||
Not yet recruiting |
NCT03755115 -
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT05027867 -
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
|
Phase 2 |